PURETECH HEALTH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 213 GBX | +3.65% |
|
+1.19% | +9.68% |
Presentation Operator MessageOperator (Operator)Greetings and welcome to the PureTech Health 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
Calendar
2024-04-24
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.65
USD
Average target price
6.205
USD
Spread / Average Target
+134.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.68% | 716M | |
| +3.13% | 43.43B | |
| +48.83% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +1.58% | 12.33B | |
| +32.83% | 12.59B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- PRTC Stock
- News PureTech Health plc
- Transcript : PureTech Health plc, H1 2021 Earnings Call, Aug 24, 2021
